Document Detail

Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy.
MedLine Citation:
PMID:  16413682     Owner:  NLM     Status:  MEDLINE    
Inflammation has been recognized as having an important role in the development and progression of atherosclerosis. Statins reduce cardiovascular events mainly by cholesterol lowering. A large number of investigations have demonstrated that administration of statin could modify inflammatory response with a concurrent fall in cardiovascular events. Despite the known benefit of statin therapy, many cardiac patients abruptly discontinue therapy because of financial constraints, forgetfulness, or side effects. More recently, several studies have shown that abrupt cessation of statin therapy during treatment could increase the incidence of cardiac events in patients with atherosclerotic heart disease. However, the mechanisms of the increased incidence of cardiovascular events after abruptly stopping statin therapy are still unknown. A few data suggest that abrupt withdrawal of statin therapy deteriorates endothelial function, result in expression of pro-inflammatory gene involved in the development and progression of atherosclerosis. We hypothesis that rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Our very recent data showed that abrupt termination of statin therapy resulted in a rapid increased C-reactive protein (CRP) and interleukin-6 (IL-6) levels in patients with hypercholesterolemia. This finding may be of important interest in the connection between inflammatory response and abrupt withdrawal of statin therapy in patients with coronary artery disease.
Jian-Jun Li; Yi-Shi Li; Jue Chen; Jin-Qi Yang
Publication Detail:
Type:  Journal Article     Date:  2006-01-18
Journal Detail:
Title:  Medical hypotheses     Volume:  66     ISSN:  0306-9877     ISO Abbreviation:  Med. Hypotheses     Publication Date:  2006  
Date Detail:
Created Date:  2006-03-27     Completed Date:  2006-06-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7505668     Medline TA:  Med Hypotheses     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  1199-204     Citation Subset:  IM    
Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / chemically induced*,  epidemiology,  immunology*
Clinical Trials as Topic
Evidence-Based Medicine
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*,  therapeutic use
Models, Immunological*
Systemic Inflammatory Response Syndrome / chemically induced*,  epidemiology,  immunology*
Withholding Treatment
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comment In:
Med Hypotheses. 2006;67(6):1466-7   [PMID:  16814483 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resi...
Next Document:  Postulating that our neurological models for musculoskeletal support, movement, and emotional expres...